{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Volders PJ"],"funding":["OncoDNA, Belgium","Belgian Society of Medical Oncologists","Velsera, USA","European Commission","Illumina"],"pagination":["66"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11893761"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(1)"],"pubmed_abstract":["The Belgian Approach for Local Laboratory Extensive Tumor Testing (BALLETT) study assessed the feasibility of using comprehensive genomic profiling (CGP) in clinical decision-making for patients with advanced cancers. This multi-center study enrolled 872 patients from 12 Belgian hospitals. CGP was performed on tumor tissues using a standardized CGP panel (523 genes) across nine laboratories with success in 93% of patients and a median turnaround time of 29 days. Actionable genomic markers were identified in 81% of patients, substantially higher than the 21% using nationally reimbursed, small panels. A national molecular tumor board (nMTB) recommended treatments for 69% of patients, with 23% receiving matched therapies. Reasons for non-compliance were highly variable across clinical sites. "],"journal":["NPJ precision oncology"],"pubmed_title":["A nationwide comprehensive genomic profiling and molecular tumor board platform for patients with advanced cancer."],"pmcid":["PMC11893761"],"funding_grant_id":["101080009"],"pubmed_authors":["Schroder D","Van Huysse J","Van der Meulen J","De Greve J","Schreuer M","Tejpar S","Aftimos P","Van Den Bulcke M","Mebis J","Van Dam PJ","Vaeyens F","Dedeurwaerdere F","De Pauw R","Canon JL","Volders PJ","Vanden Bempt I","Prenen H","de Azambuja E","Punie K","Loontiens S","Cuppens K","Beniuga G","Lambin S","Maes B","Rutten A","van Marcke C","Martens G","Rottey S","Froyen G","Decoster L"],"additional_accession":[]},"is_claimable":false,"name":"A nationwide comprehensive genomic profiling and molecular tumor board platform for patients with advanced cancer.","description":"The Belgian Approach for Local Laboratory Extensive Tumor Testing (BALLETT) study assessed the feasibility of using comprehensive genomic profiling (CGP) in clinical decision-making for patients with advanced cancers. This multi-center study enrolled 872 patients from 12 Belgian hospitals. CGP was performed on tumor tissues using a standardized CGP panel (523 genes) across nine laboratories with success in 93% of patients and a median turnaround time of 29 days. Actionable genomic markers were identified in 81% of patients, substantially higher than the 21% using nationally reimbursed, small panels. A national molecular tumor board (nMTB) recommended treatments for 69% of patients, with 23% receiving matched therapies. Reasons for non-compliance were highly variable across clinical sites. ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Mar","modification":"2026-06-02T19:16:51.376Z","creation":"2025-04-04T02:50:38.545Z"},"accession":"S-EPMC11893761","cross_references":{"pubmed":["40065106"],"doi":["10.1038/s41698-025-00858-0"]}}